With a five-year survival rate that’s already less than 10 percent, pancreatic cancer is considered among the deadliest forms of this disease known to man. For those who smoke, a diagnosis of pancreatic cancer may pose an even higher mortality risk, researchers say.

A recent study that looked into the links between smoking and pancreatic cancer death risks revealed very disturbing findings. Smokers, researchers say, witnessed a 40 percent reduction in survival likelihood versus their counterparts who had never smoked.

To arrive at their findings, researchers dove into data related to smoking status and more than 1,000 pancreatic cancer patients from the United States. Researchers say the data showed that smokers had a 37 percent increased risk of death overall. The driving factor behind the mortality rate, researchers believe, is partially attributed to high levels of cotinine, a metabolite of nicotine. Researchers noted there was no reduction in survival rate for former smokers, which means quitting may make a big difference on this front.

Pancreatic cancer is expected to strike an estimated 53,000 Americans in the coming year. About 43,000 people die from this causation each year in the United States. The disease has no widely available early screening tool and is known to be highly resistant to standard forms of therapy. Considering that most cases are diagnosed in later stages, the overall survival rate for pancreatic cancer is extremely low. Researchers, however, say that quitting smoking or avoiding it all together could have an impact on an individual patient’s outcome should this disease develop.

Pancreatic cancer is associated with a long list of risk factors, some changeable and some not. Smoking happens to be one of the risks that people can eliminate. New onset diabetes, obesity, chronic pancreatitis and family history may also elevate risks. People who are concerned about pancreatic cancer are urged to talk to their doctors. If smoking is a concern, healthcare providers can assist with cessation advice.

With a five-year survival rate that’s less than 10 percent, pancreatic cancer is considered one of the most difficult forms of this disease to treat. Often diagnosed in later stages, this form of cancer is noted for having tumors that simply do not respond to common treatments, such as chemotherapy. Researchers, however, believe they may have uncovered a way to produce more positive results through treatment. The method involves taking a two-step approach to chemotherapy.

A recent study was conducted to determine if a more in-depth approach to chemotherapy would have an impact on results. The treatment involved the use of Fasudil, a drug used on stroke victims, for a three-day period. Researchers believed the drug might prepare tumors to be more receptive to standard chemotherapy. Once the course of Fasudil was completed, chemotherapy began.

The results of the small-scale trial were quite promising. Researchers found that the two-step treatment was able to double survival time while impeding the spread of cancer. The trial was conducted on mice and using tumor samples from human patients, as well.

While more work needs to be done to determine if the approach would be beneficial for more widespread use, researchers say it is a positive step forward. Clinical trials to test safety for patient use are planned and the off-patent Fasudil, scientists say, is ripe for repurposing for uses such as fighting pancreatic cancer.

It is estimated that more than 53,000 Americans will be diagnosed with pancreatic cancer in the coming year. An estimated 43,000 will die from this cause. With no early screening test widely available and few symptoms, if any, at its onset, pancreatic cancer remains a very difficult form of the disease to detect and treat. The latest research into a two-step approach may someday help make treatment more effective. In the meantime, people at risk for this condition are strongly urged to talk to their healthcare providers.

A link between potentially deadly pancreatic cancer and new onset diabetes has long been known. While the two conditions don’t always go hand-in-hand, the frequency rate has been enough for researchers to begin probing the connection between pancreatic cancer and the rare type 3c diabetes. A recent study has shed light on a biomarker that may someday lead to earlier detection and lifesaving treatment in diabetics who also happen to have pancreatic cancer.

In studying the connection between the two conditions, researchers found a hormone called Neuromedin U. This hormone decreases insulin levels in the body, essentially creating diabetic symptoms. Researchers have found that Neuromedin U is not typically created in the pancreas. It is believed to instead be produced and secreted into the blood by cells associated with early-stage pancreatic cancer.

The recent study is especially encouraging for a few important reasons. Firstly, the hormone may hold the key as to why people who are not obese present with diabetes later in life and are also estimated to be 20-fold more likely to develop pancreatic cancer within a short period after diabetes diagnosis. Secondly, the hormone may serve as a way for researchers to develop a tool for early detection of pancreatic cancer. This, in turn, could result in much more positive outcomes for patients with this disease.

The American Cancer Society estimates that some 53,000 people in the U.S. will be diagnosed with pancreatic cancer in the coming year. About 43,000 people will die from the cause in the next year alone. Very difficult to detect when it is in its earlier stages and nearly impossible to treat in later stages, pancreatic cancer is considered one of the deadliest form of the disease. The hormone Neuromedin U may someday soon serve as a way to open the door to earlier detection and more successful treatment.

Transforming pancreatic cancer from one of the deadliest forms of this disease into a less terrifying prospect is the focus of much study as of late. With a five-year survival rate at present that is less than 10 percent, much work remains to be done. According to the American Cancer Society, about 53,000 people in the U.S. are diagnosed each year. An estimated 43,000 die from the cause. Developing a reliable, accurate tool for early detection, many experts say, could push those numbers in a much more positive direction.

As it stands currently, pancreatic cancer is an extremely difficult disease to detected. This is partially due to the location of the pancreas deep inside the body. This fact is complicated by the reality that pancreatic cancer tends to present with no symptoms initially. If symptoms are present, they tend to be very vague and quite easy to link to a long list of other possible causes.

While a reliable tool for early screening like those used for prostate and breast cancer is not yet available, this prospect is the focus of much research. One ongoing study involves the use of a blood test that is able to detect biomarkers that have been linked to pancreatic cancer. This detection tool was able to find early stage pancreatic cancer in a whopping 90 percent of patients who took part in a recent pilot study. That study, however, included fewer than 60 patients. Although still a way off from being green lighted for more widespread use, the blood test could be a game changer in the detection and treatment of pancreatic cancer.

People who are at risk for the development of pancreatic cancer are urged to speak with their doctors about prevention and symptoms to watch for. Early detection of this form of cancer is considered critical for improving the potential for a positive outcome.

Each year, almost as many people who are diagnosed with pancreatic cancer in the United States die from the disease. The American Cancer Society estimates about 53,000 Americans will be diagnosed with this form of cancer in the coming year. Some 43,000 will lose their life. A disease that strikes men and women alike, pancreatic cancer’s grim survival statistics are largely associated with difficulty in detecting the condition in its earlier stages and a lack of effective treatment to halt its growth.

Researchers believe they may have found a way to better manage pancreatic cancer after it forms. Their works involves a protein known as S100P. This protein is known to overexpress when pancreatic cancer is present, working to signal changes in the body that promote the growth and spread of cancer cells. To change this, researchers have created a compound that may stop S100P from activating. This, in turn, could slow or halt the development of pancreatic cancer. A total of nearly 20 possible drugs have been identified that may prevent pancreatic cancer cells from migrating.

Although still very much in the testing phases, this line of research is offering great hope for the eventual treatment of pancreatic cancer. This line of work to slow growth and stop spread comes as other researchers are diligently testing possible early screening procedures. Success in both arenas could have a very strong and positive impact on the grim numbers currently associated with pancreatic cancer.

Pancreatic cancer is considered rare, but its high mortality rate makes it a very big concern for doctors and patients alike. People at high risk for the development of this form of cancer are urged to speak with their healthcare providers about cutting risks that can be addressed. New onset diabetes, chronic pancreatitis, family history, tobacco use and obesity are all potential risk factors.

Pancreatic cancer has one of the grimmest survival rates of all forms of this disease in the United States. It is estimated that some 53,000 Americans will be diagnosed with this form of cancer in the coming year. About 43,000 people will lose their lives to this cause.

Researchers are hoping a new breakthrough in early screening technology may soon turn those numbers in a positive direction. The breakthrough in question is a simple blood test that is showing promise in being able to detect pancreatic cancer in its earlier, more treatable stages.

Although still very much under study, the blood test is showing much promise. It focuses in on a particular protein in the blood that tends to over express when pancreatic tumors are present. Researchers have developed a biosensor that enables them to quantify the amount of this protein in the blood to see if pancreatic cancer is likely present. A recent pilot study was conducted to test the viability. The study included a group of healthy people and a sampling of patients confirmed to have pancreatic cancer at varying stages. People with chronic inflammation of the pancreas were also included. The results showed the biosensor was able to successfully identify people with pancreatic cancer, even those in earlier stages of the disease.

While it could still be some time before this test is widely available, the pilot study has paved the way for a larger clinical trial. How soon those results might be available remains unclear.
Pancreatic cancer is considered one of the deadliest forms of cancer. Clinicians have long held that might not be the case if an easier, more accurate way to detect this condition in early stages was available. Whether the new blood test will prove to be that remains to be seen. The pilot study, however, has created great hope that someday soon pancreatic cancer might be more readily treatable courtesy of earlier detection techniques.

As pancreatic cancer remains among the deadliest forms of this disease, researchers are working hard to identify ways people at risk may lower their chances of developing the condition. Several studies have now shed light on the potential a very simple, over-the-counter medication may offer in providing some protection against this form of cancer. Aspirin, as it turns out, may do more than help people prevent heart attacks and treat headaches. New research indicates that this common substance can lower the risk of pancreatic cancer by nearly 50 percent.

One of the more recent studies to delve into the potential aspirin holds in preventing pancreatic cancer involved hundreds of patients who were diagnosed with the disease. These people were asked about their aspirin use and were matched with control patients. Researchers ultimately found that people who defined themselves as regular users of aspirin had significantly lower risk of developing pancreatic cancer. Analysis of the data showed pancreatic cancer risk dropped for each cumulative year of aspirin use. Researchers also took into account nearly two dozen other studies on the topic that also showed potential benefits of routine aspirin use.

Pancreatic cancer is estimated to strike more than 53,000 Americans each year. The disease claims about 41,000 lives. With a five-year survival rate of less than 10 percent, the disease is considered one of the deadliest forms of cancer.

Pancreatic cancer has a number of risk factors that people can control and some they cannot. Risks include obesity, tobacco use, chronic pancreatitis, family history, genetic links and diabetes, among others. People who are at risk are strongly urged to speak with their healthcare providers about prevention. Introducing low-dose aspirin use into the daily routine may be beneficial, studies show, but it is strongly recommended that medical advice be sought before doing so. Long-term aspirin use may also pose its own risks.

While any diagnosis of cancer is life changing, a diagnosis of pancreatic cancer can be especially bad. This condition strikes an estimated 53,000 Americans annually and claims about 43,000 lives. With a five-year survival rate that is especially low, less than 10 percent, prognosis for most patients is simply not good. A new technique being explored is showing signs of promise in helping people extend life expectancy in some cases. Called irreversible electroporation, the procedure targets pancreatic cancer tumors at their source.

Irreversible electroporation is sometimes used after other treatments have been proven ineffective. Chemotherapy and radiation, for example, may be performed first. After time, however, pancreatic cancer cells tend to become resistant to chemo medications. The new procedure is still under study and may serve to extend life when other treatment options have been exhausted. It involves creating small incisions to facilitate the placement of long needle probes that essentially bracket the tumor. Ultrasound is used to guide placement. Once a tumor is bracketed, the probes are electrified with a high voltage. This, in turn, causes cancer cells to die.

Although only performed a few hundred times so far, the new procedure is being credited with extending lives of some pancreatic cancer patients. In some cases, the extension has been as much as two years. The procedure is best suited for people with tumors that are smaller than 4 centimeters and only in patients who are otherwise healthy. People with heart conditions, for example, are not good candidates due to the potential for cardiac complications with the electrical voltage.

People who are diagnosed with pancreatic cancer are urged to work with their doctors to determine the best treatments to explore in their unique cases. The most appropriate treatment recommendations will come from a physician with knowledge about a patient’s particular case. People who are at risk for pancreatic cancer are urged to talk to their doctors, as well, to identify any potential measures that may lower risk, such as losing weight or quitting smoking.

Pancreatic cancer has one of the deadliest records of all forms of this disease. With a five-year survival rate that doesn’t even rank in the double digits, this disease claims more than 40,000 American lives each year. While a number of obstacles have stood in the way of advancements in treating this form of cancer, researchers believe they may have pinpointed a way to make chemotherapy treatments more effective for some. The simple addition of Vitamin A may make a tremendous difference, a recent study indicates.

The study in question involved the use of a particular form of Vitamin A. The vitamin was used in high doses in conjunction with chemo because it enabled researchers to target “stromal cells.” These are cells that surround cancer cells, impeding routine chemotherapy treatments from having an effect. When the combination was used in mice, the results were highly promising.

Just how soon the combination therapy might be made available to humans remains unclear. Researchers, however, were so pleased with the results they intend to move on to clinical trials. The findings offer hope that someday soon chemotherapy might be a more viable treatment option for this form of cancer.

Pancreatic cancer is deemed among the most difficult forms of the disease to treat because of its nature. This type of cancer forms deep within the body and presents initially with few, if any, symptoms. When symptoms do arise, they tend to be vague and mistaken for other, less troublesome conditions.

People who are at risk for pancreatic cancer are urged to talk with their healthcare providers. Common risk factors for the disease include diabetes, chronic pancreatitis and family history. While no routine screening tool is available for widespread use, people in high risk categories will find some screening mechanisms may be available to them.

For the 53,000 Americans anticipated to be diagnosed with pancreatic cancer in the coming year, obtaining proper nutrition during their battles against the disease will likely be a tremendous challenge. This particular form of cancer has the ability to interfere with appetite long before chemotherapy or other treatments are put into action. Due to its unique nature, healthcare providers recommend that patients work closely with nutrition experts.

Pancreatic cancer is able to interfere with nutrition for several reasons. Firstly, it is known to cause nausea, fatigue and pain. These symptoms on their own can alter appetite greatly. Complicating matters is the fact that pancreatic cancers are able to release hormones that make people feel like they don’t want to drink or eat. It can also cause changes in taste that make eating unpleasant.

Since nutrition is critical for giving patients the strength they need to endure treatments and enjoy life inasmuch is possible, there are tips that can help boost nutritional standing. Dietary experts recommend the following for people facing pancreatic cancer:

• Eating nutrition-dense foods – Foods like oatmeal, avocado and quinoa pack a lot of energy into every bite.
• Consuming fruit – Processed sugars can be difficult for a patient’s body to endure, but healthy sweet options like fruit can be helpful.
• Eating small meals – It is often best to eat small, frequent meals that are nutritionally dense. This can ensure a steady flow of nutrition while helping keep nausea at bay.
• Keeping a log – It can be helpful to keep a journal of foods the body has poor reactions to. Make sure to share this with medical professionals. They may be able to offer insights on other items to steer clear of and new foods to try that might not create reactions.

People who are diagnosed with pancreatic cancer are urged to talk with their healthcare providers about nutrition. If appetite is a concern, there are ways doctors can help ensure patients can address symptoms to promote a healthier diet before, during and after treatments.